Literature DB >> 18641006

Prognostic factors in 1,038 women with metastatic breast cancer.

R Largillier1, J-M Ferrero, J Doyen, J Barriere, M Namer, V Mari, A Courdi, J M Hannoun-Levi, F Ettore, I Birtwisle-Peyrottes, C Balu-Maestro, P Y Marcy, I Raoust, M Lallement, E Chamorey.   

Abstract

BACKGROUND: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with MBC represent a heterogeneous group whose prognosis and outcome may be dependent on host factors. The purpose of the present study was dual: first, to draw up a list of factors easily available in everyday clinical practice requiring no sophisticated or costly methods and second, to provide results from a large cohort of women who underwent diagnostic and treatment at a single institution. PATIENTS AND METHODS: From 1975 to 2005, a total of 1,038 women with MBC during their follow-up were included in this retrospective analysis. Patients were subsequently assigned to five groups according to the period of metastatic diagnosis.
RESULTS: It is shown that age at initial diagnosis, hormonal receptor status and site of metastasis are the most relevant prognostic factors for predicting survival from the time of metastastic occurrence. It is also shown that a metastasis-free interval is an easily and immediately available multifactorial prognostic index reflecting the multiparametric variability of the disease.
CONCLUSION: These fundamental observations may assist physicians in evaluating the survival potential of patients and in directing them toward the appropriate therapeutic decision.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641006      PMCID: PMC2733115          DOI: 10.1093/annonc/mdn424

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  26 in total

Review 1.  Survival, quality of life and breast cancer.

Authors:  P Mosconi; M Colozza; M De Laurentiis; S De Placido; M Maltoni
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

2.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.

Authors:  E F Solomayer; I J Diel; G C Meyberg; C Gollan; G Bastert
Journal:  Breast Cancer Res Treat       Date:  2000-02       Impact factor: 4.872

3.  Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer.

Authors:  M Robain; J Y Pierga; M Jouve; B Asselain; V Diéras; P Beuzeboc; T Palangié; T Dorval; J M Extra; S Scholl; P Pouillart
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

Review 4.  Second consensus on medical treatment of metastatic breast cancer.

Authors:  S Beslija; J Bonneterre; H Burstein; V Cocquyt; M Gnant; P Goodwin; V Heinemann; J Jassem; W J Köstler; M Krainer; S Menard; T Petit; L Petruzelka; K Possinger; P Schmid; E Stadtmauer; M Stockler; S Van Belle; C Vogel; N Wilcken; C Wiltschke; C C Zielinski; H Zwierzina
Journal:  Ann Oncol       Date:  2006-07-10       Impact factor: 32.976

5.  Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy.

Authors:  M Ryberg; D Nielsen; K Osterlind; T Skovsgaard; P Dombernowsky
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

6.  Classification of patients with disseminated cancer of the breast.

Authors:  S J Cutler; J A Ardyce; S G Taylor
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

7.  Multivariate analysis of prognostic factors in metastatic breast cancer.

Authors:  G N Hortobagyi; T L Smith; S S Legha; K D Swenerton; E A Gehan; H Y Yap; A U Buzdar; G R Blumenschein
Journal:  J Clin Oncol       Date:  1983-12       Impact factor: 44.544

8.  Revision of the American Joint Committee on Cancer staging system for breast cancer.

Authors:  S Eva Singletary; Craig Allred; Pandora Ashley; Lawrence W Bassett; Donald Berry; Kirby I Bland; Patrick I Borgen; Gary Clark; Stephen B Edge; Daniel F Hayes; Lorie L Hughes; Robert V P Hutter; Monica Morrow; David L Page; Abram Recht; Richard L Theriault; Ann Thor; Donald L Weaver; H Samuel Wieand; Frederick L Greene
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

9.  Breast cancer with synchronous metastases: trends in survival during a 14-year period.

Authors:  Fabrice Andre; Khemaies Slimane; Thomas Bachelot; Arianne Dunant; Moise Namer; Alain Barrelier; Omar Kabbaj; Jean Philippe Spano; Hugo Marsiglia; Roman Rouzier; Suzette Delaloge; Marc Spielmann
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

10.  Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

Authors:  Jenny Chang; Gary M Clark; D Craig Allred; Syed Mohsin; Gary Chamness; Richard M Elledge
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

View more
  117 in total

1.  Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Authors:  Hyman Muss; Javier Cortes; Linda T Vahdat; Fatima Cardoso; Chris Twelves; Jantien Wanders; Corina E Dutcus; Jay Yang; Seth Seegobin; Joyce O'Shaughnessy
Journal:  Oncologist       Date:  2014-03-28

2.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

3.  Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy.

Authors:  Shogo Nakamoto; Junichiro Watanabe; Shoichiro Ohtani; Satoshi Morita; Masahiko Ikeda
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

4.  Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.

Authors:  Ummugul Uyeturk; Berna Oksuzoglu; Tulay Akman; Ibrahim Turker; Nur Sener; Didem Tastekin; Oznur Bal; Veli Berk; Ulku Yalcintas Arslan; Zuhat Urakci; Cemil Bilir; Ugur Yilmaz; Dogan Yazilitas; Arife Ulas; Ozlem Uysal Sonmez; Burcin Budakoglu; Sener Cihan; Mukremin Uysal
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

5.  Quality of life and metastatic breast cancer: the role of body image, disease site, and time since diagnosis.

Authors:  Sara I McClelland; Kathryn J Holland; Jennifer J Griggs
Journal:  Qual Life Res       Date:  2015-06-03       Impact factor: 4.147

6.  Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Authors:  Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Nadia Harbeck; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-20       Impact factor: 4.553

7.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

8.  The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.

Authors:  Sadia Tasleem; Jarlath C Bolger; Michael E Kelly; Michael R Boland; Dermot Bowden; Karl J Sweeney; Carmel Malone
Journal:  Ir J Med Sci       Date:  2018-02-01       Impact factor: 1.568

9.  Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Authors:  Amye J Tevaarwerk; Robert J Gray; Bryan P Schneider; Mary Lou Smith; Lynne I Wagner; John H Fetting; Nancy Davidson; Lori J Goldstein; Kathy D Miller; Joseph A Sparano
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

10.  Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.

Authors:  C K Lee; M R Stockler; A S Coates; V Gebski; S J Lord; R J Simes
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.